Peking University Cancer Hospital & Institute
445
110
122
54
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
1.1%
5 terminated/withdrawn out of 445 trials
91.5%
+5.0% vs industry average
10%
45 trials in Phase 3/4
6%
3 of 54 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (445)
Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node (S-M-O-O-T-H)
Role: collaborator
18F-grazy-02 PET/CT of Granzyme B Expression for Monitoring Immunotherapy
Role: lead
A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC
Role: collaborator
Development and Validation of a Colorectal Cancer Diagnostic Model
Role: lead
Construction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging Probe
Role: lead
Preoperative ROS1-TKI Therapy for ROS1 Fusion-Positive Locally Advanced Lung Adenocarcinoma
Role: lead
Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC
Role: lead
SHR-A1904 in Advanced Colorectal Cancer: an Exploratory Study
Role: lead
A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma
Role: lead
Fosrolapitant and Palonosetron for the Prevention of Antibody-drug Conjugate-induced Nausea and Vomiting
Role: lead
AI-Driven Tumor Response Evaluation for Solid Tumors
Role: collaborator
Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial
Role: collaborator
Patient-Derived Organoid-on-a-Chip Model for Personalized Prediction of Chemotherapy Efficacy in Pancreatic Cancer
Role: collaborator
A Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors.
Role: collaborator
Non-Operative Management and Following Immunotherapy for Colorectal Cancer and Other GI Cancers
Role: lead
Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer
Role: lead
Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC
Role: collaborator
EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC
Role: collaborator
Safety and Efficacy of NOM and OPFS Versus RO for dMMR/MSI-H or POLE-Mutated Gastrointestinal Cancers
Role: lead
68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid Tumors
Role: lead